Newsletter | January 23, 2025

01.23.25 -- How To Establish A Win-Win Relationship With Your CDMO

SPONSOR

With a third wave of biologics patents expiring, the race is on to seize the booming opportunities in the fast-evolving biosimilars field. What’s driving the patent scramble? What hurdles in manufacturing, regulation, and market access must be cleared for biosimilars to thrive? And how are global industry leaders carving out strategies to dominate the market? Don't miss Bioprocess Online Live happening February 4th. Registration is completely free, thanks to the support of Cytiva and Ecolab Life Sciences.

FEATURED EDITORIAL

7 Focus Areas To Establish A Win-Win Relationship With Your CDMO

Working with a CDMO doesn’t always go as planned. This article outlines the factors that will impact project success and set up a “win-win” relationship.

INDUSTRY INSIGHTS

Software Simplifies 21 CFR Part 11 And Annex 11 Compliance

Learn about 21 CFR Part 11 and Annex 11 in biomanufacturing as well as software designed to aid compliance with electronic records and signatures regulations.

NEWS HEADLINES

Teva Announces Collaboration To Commercialize Formycon's Biosimilar Candidate To Eylea® (aflibercept) In Major Parts Of Europe And In Israel

Formycon And Fresenius Kabi Canada Receive Health Canada's Approval For FYB202/Otulfi (ustekinumab), A Biosimilar To Stelara

Samsung Bioepis And Teva Enter Into A Strategic Partnership For Commercialization Of EPYSQLI® (eculizumab-aagh) In The United States

Sandoz To Confirm Strategic Roadmap And Highlight Pipeline Catalysts At 43rd Annual J.P. Morgan Healthcare Conference

SOLUTIONS

Bioreactors Designed For Cell Growth And Expansion